Citation Impact
Citing Papers
Cyclic GMP-AMP Synthase Is a Cytosolic DNA Sensor That Activates the Type I Interferon Pathway
2012 StandoutScience
Identification of a Primary Target of Thalidomide Teratogenicity
2010 StandoutScience
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
2013 StandoutScienceNobel
Immunological aspects of cancer chemotherapy
2007
UV Light Potentiates STING (Stimulator of Interferon Genes)-dependent Innate Immune Signaling through Deregulation of ULK1 (Unc51-like Kinase 1)
2015 StandoutNobel
EGFR Antagonists in Cancer Treatment
2008 Standout
Bioorthogonal Chemistry: Fishing for Selectivity in a Sea of Functionality
2009 StandoutNobel
Role of T cells and tumour necrosis factor in antitumour activity and toxicity of flavone acetic acid
1990
Altered immune responses in mice lacking inducible nitric oxide synthase
1995 StandoutNature
Elements of cancer immunity and the cancer–immune set point
2017 StandoutNature
The Ubiquitin Ligase TRIM56 Regulates Innate Immune Responses to Intracellular Double-Stranded DNA
2010
Interferons at age 50: past, current and future impact on biomedicine
2007
Inducible Nitric-oxide Synthase and Nitric Oxide Production in Human Fetal Astrocytes and Microglia
1997 StandoutNobel
Structure-Function Analysis of STING Activation by c[G(2′,5′)pA(3′,5′)p] and Targeting by Antiviral DMXAA
2013
cGAS produces a 2′-5′-linked cyclic dinucleotide second messenger that activates STING
2013 StandoutNature
Species‐specific detection of the antiviral small‐molecule compound CMA by STING
2013
Inhibition of microsome-mediated binding of benzo[a]pyrene to DNA by flavonoids either in vitro or after dietary administration to rats
1992
Synthesis and biological study of a flavone acetic acid analogue containing an azido reporting group designed as a multifunctional binding site probe
2005
A convenient synthesis of anthranilic acids by Pd-catalyzed direct intermolecular ortho-C–H amidation of benzoic acids
2012
NLRP6 Inflammasome Regulates Colonic Microbial Ecology and Risk for Colitis
2011 Standout
Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity
2015 Standout
Structure-Guided Reprogramming of Human cGAS Dinucleotide Linkage Specificity
2014 StandoutNobel
The AIM2 inflammasome is essential for host defense against cytosolic bacteria and DNA viruses
2010 Standout
Flavone acetic acid suppresses human peripheral blood lymphocyte and human colonic lamina propria lymphocyte DNA synthesis
1990
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
Nitric oxide synthases: Roles, tolls, and controls
1994 Standout
Disrupting tumour blood vessels
2005
Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
2014
The RNA Sensor RIG-I Dually Functions as an Innate Sensor and Direct Antiviral Factor for Hepatitis B Virus
2014 StandoutNobel
Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia
2011 Standout
The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy
2007
The biochemistry and medical significance of the flavonoids
2002 Standout
The Next Hurdle in Cancer Immunotherapy: Overcoming the Non–T-Cell–Inflamed Tumor Microenvironment
2015
Interaction of Nitric Oxide Synthase with the Postsynaptic Density Protein PSD-95 and α1-Syntrophin Mediated by PDZ Domains
1996 Standout
Immunity, Inflammation, and Cancer
2010 Standout
TRIF Licenses Caspase-11-Dependent NLRP3 Inflammasome Activation by Gram-Negative Bacteria
2012
Organocatalytic Asymmetric Hydrolysis of Epoxides
2014 StandoutNobel
Interferons and viruses: an evolutionary arms race of molecular interactions
2015 StandoutNobel
IFNβ-dependent increases in STAT1, STAT2, and IRF9 mediate resistance to viruses and DNA damage
2013 StandoutNobel
Vascular‐targeting therapies for treatment of malignant disease
2004
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
2017 Standout
Tumor-peptide-pulsed dendritic cells isolated from spleen or cultured in vitro from bone marrow precursors can provide protection against tumor challenge
1997
Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores
2016 StandoutNature
Inflammatory caspases are innate immune receptors for intracellular LPS
2014 StandoutNature
Innate Immune Recognition of an AT-Rich Stem-Loop DNA Motif in the Plasmodium falciparum Genome
2011
Mechanisms and Functions of Inflammasomes
2014 Standout
Mouse B7-H3 induces antitumor immunity
2003
Targeting DNA topoisomerase II in cancer chemotherapy
2009 Standout
5,6-Dimethylxanthenone-4-acetic Acid (DMXAA) Activates Stimulator of Interferon Gene (STING)-dependent Innate Immune Pathways and Is Regulated by Mitochondrial Membrane Potential
2012
Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond
2019 Standout
Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido
2011 StandoutNobel
Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan
2003 StandoutNature
VEGF in Signaling and Disease: Beyond Discovery and Development
2019 Standout
IFI16 is an innate immune sensor for intracellular DNA
2010
Angiogenesis as a therapeutic target
2005 StandoutNature
Tumor Angiogenesis
2008 Standout
Inflammasomes in health and disease
2012 StandoutNature
Micelle-Encapsulated Quantum Dot-Porphyrin Assemblies as in Vivo Two-Photon Oxygen Sensors
2015 StandoutNobel
Roles of nitric oxide in tumor growth.
1995
RTP4 inhibits IFN-I response and enhances experimental cerebral malaria and neuropathology
2020 StandoutNobel
The impact of plant flavonoids on mammalian biology: implications for immunity, inflammation and cancer
2017
SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade
2008 StandoutNobel
A host type I interferon response is induced by cytosolic sensing of the bacterial second messenger cyclic-di-GMP
2009
Flavone-8-acetic acid augments systemic natural killer cell activity and synergizes with IL-2 for treatment of murine renal cancer.
1988
Augmentation of natural killer activity, induction of IFN and development tumor immunity during the successful treatment of established murine renal cancer using flavone acetic acid and IL-2.
1988
Peptidic degron for IMiD-induced degradation of heterologous proteins
2019 StandoutNobel
Vascular Targeting Agents as Cancer Therapeutics
2004
Nanotechnology for Multimodal Synergistic Cancer Therapy
2017 Standout
Interferon-Stimulated Genes: A Complex Web of Host Defenses
2014 StandoutNobel
Regulation of biosynthesis of nitric oxide.
1994
Mouse, but not Human STING, Binds and Signals in Response to the Vascular Disrupting Agent 5,6-Dimethylxanthenone-4-Acetic Acid
2013
Mice lacking inducible nitric oxide synthase are not resistant to lipopolysaccharide-induced death.
1995 StandoutNobel
B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome
2007 StandoutNobel
The Effects of Plant Flavonoids on Mammalian Cells:Implications for Inflammation, Heart Disease, and Cancer
2000 Standout
Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth
1997 StandoutNobel
Cyclic GMP–AMP Synthase Is the Cytosolic Sensor of Plasmodium falciparum Genomic DNA and Activates Type I IFN in Malaria
2017
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
2005 StandoutScience
Clonal analysis of cytolytic T lymphocyte specificity. I. Phenotypically distinct sets of clones as the cellular basis of cross-reactivity to alloantigens.
1980
Specificity in the activation and inhibition by flavonoids of benzo[a]pyrene hydroxylation by cytochrome P-450 isozymes from rabbit liver microsomes.
1981
Flavonoids, a class of natural products of high pharmacological potency
1983
Human Cd4+ T Lymphocytes Consistently Respond to the Latent Epstein-Barr Virus Nuclear Antigen Ebna1
2000 StandoutNobel
Transition Metal-Catalyzed C–H Amination: Scope, Mechanism, and Applications
2017 Standout
Structural Basis of Type II Topoisomerase Inhibition by the Anticancer Drug Etoposide
2011 StandoutScience
Crbn I391V is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice
2018
N‐Carboxyanhydride Polymerization of Glycopolypeptides That Activate Antigen‐Presenting Cells through Dectin‐1 and Dectin‐2
2018 StandoutNobel
Cytochrome P450 and Chemical Toxicology
2007
Promising Targets for Cancer Immunotherapy: TLRs, RLRs, and STING-Mediated Innate Immune Pathways
2017
Works of Lai‐Ming Ching being referenced
The chemotherapeutic agent DMXAA potently and specifically activates the TBK1–IRF-3 signaling axis
2007
IFN- β -Dependent Inhibition of Tumor Growth by the Vascular Disrupting Agent 5,6-Dimethylxanthenone-4-Acetic Acid (DMXAA)
2008
Neutrophil Influx and Chemokine Production during the Early Phases of the Antitumor Response to the Vascular Disrupting Agent DMXAA (ASA404)
2009
Cell line selectivity and DNA breakage properties of the antitumour agent N-[2-(Dimethylamino)ethyl]acridine-4-carboxamide: role of DNA topoisomerase II
1988
Activation of mitogen-activated protein kinases by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) plays an important role in macrophage stimulation
2011
Antitumour activity of the novel immune modulator 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice lacking the interferon-gamma receptor
1998
Immunomodulatory Actions of Xanthenone Anticancer Agents
1997
Labeling of Oxidizable Proteins with a Photoactivatable Analog of the Antitumor Agent DMXAA: Evidence for Redox Signaling in Its Mode of Action
2010
Induction of STAT and NFκB activation by the antitumor agents 5,6-dimethylxanthenone-4-acetic acid and flavone acetic acid in a murine macrophage cell line
1999
Mechanisms of tumor vascular shutdown induced by 5,6‐dimethylxanthenone‐4‐acetic acid (DMXAA): Increased tumor vascular permeability
2005
Enhancement of in vitro cytotoxicity of mouse peritoneal exudate cells by flavone acetic acid (NSC 347512)
1988
DMXAA: An antivascular agent with multiple host responses
2002
Activation of the Nucleotide Oligomerization Domain Signaling Pathway by the Non-bacterially Derived Xanthone Drug 5′6-Dimethylxanthenone-4-acetic Acid (Vadimezan)
2010
Formation of an N-formylkynurenine-derived fluorophore and its use for measuring indoleamine 2,3-dioxygenase 1 activity
2013
Hyporesponsiveness of macrophages from (endotoxin-resistant) mice to the antitumour agent flavone acetic acid (NSC 347512)
1989
Connexin hemichannel induced vascular leak suggests a new paradigm for cancer therapy
2014
Nitric oxide production in endotoxin-resistant C3H/HeJ mice stimulated with flavone-8-acetic acid and xanthenone-4-acetic acid analogues
1992
The antitumour agent 5,6-dimethylxanthenone-4-acetic acid acts in vitro on human mononuclear cells as a co-stimulator with other inducers of tumour necrosis factor
2001
Reduction of cytotoxic effector cell activity in colon 38 tumours following treatment with flavone acetic acid
1989
Metabolism of Thalidomide in Liver Microsomes of Mice, Rabbits, and Humans
2004
Induction of tumour necrosis factor-? by single and repeated doses of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid
1995
Induction of natural killer cell activity by the antitumour compound flavone acetic acid (NSC 347 512)
1987
Induction of tumour necrosis factor and interferon-γ in cultured murine splenocytes by the antivascular agent DMXAA and its metabolites
2003
Evidence for the production of nitric oxide by activated macrophages treated with the antitumor agents flavone-8-acetic acid and xanthenone-4-acetic acid.
1990
Resistance of Cultured Lewis Lung Carcinoma Cell Lines to Tiazofurin<xref ref-type="fn" rid="FN2">2</xref>
1987
Activation of Tumor-Associated Macrophages by the Vascular Disrupting Agent 5,6-Dimethylxanthenone-4-Acetic Acid Induces an Effective CD8+ T-Cell–Mediated Antitumor Immune Response in Murine Models of Lung Cancer and Mesothelioma
2005
Improvement of the antitumor activity of intraperitoneally and orally administered 5,6-dimethylxanthenone-4-acetic acid by optimal scheduling.
2003
Stimulation of mammalian epoxide hydrase activity by flavones
1980
Thalidomide Pharmacokinetics and Metabolite Formation in Mice, Rabbits, and Multiple Myeloma Patients
2004
Synthesis and Biological Activity of Azido Analogues of 5,6-Dimethylxanthenone-4-acetic Acid for Use in Photoaffinity Labeling
2007
Spontaneous clones of cytotoxic T cells in culture III. Discriminatory lysis of pairs of syngeneic blasts induced by different mitogens
1977
Tumor-dependent increased plasma nitrate concentrations as an indication of the antitumor effect of flavone-8-acetic acid and analogues in mice.
1991
The Vascular Disrupting Agent, DMXAA, Directly Activates Dendritic Cells through a MyD88-Independent Mechanism and Generates Antitumor Cytotoxic T Lymphocytes
2007
Spontaneous clones of cytotoxic T cells in culture
1977
Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci.
2001
The clonal analysis of cytotoxic lymphocytes against 2,4,6‐trinitrophenyl (TNP)‐modified cells
1979
Clones of cytotoxic lymphocytes in culture: the difference in specificity between stimulated and nonstimulated cytotoxic lymphocytes
1977
Interferon-inducible protein 10 induction and inhibition of angiogenesis in vivo by the antitumor agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
2001
Activation of LPS-inducible genes by the antitumor agent 5,6-dimethylxanthenone-4-acetic acid in primary murine macrophages. Dissection of signaling pathways leading to gene induction and tyrosine phosphorylation.
1994